TROPION-Lung01 Study Design and Baseline demographics
PFS by BICR Across Subgroups
Events/n
Hazard
Dato-DXd
ICC
ratio
All patients
212/365 235/367
0.63
Age at randomisation
<65 years
163/274 190/295
0.64
≥65 years
Race
Asian
49/91
88/146
45/72
0.65
101/152
0.70
Non-Asian
109/187 119/183
0.59
ECOG performance status
0
119/197 136/220
0.73
1
91/165 98/145
0.52
Geographic region
US, Canada, Europe
110/186 112/182
0.62
Rest of World*
102/179 123/185
0.66
Number of previous lines
1
128/229 145/225
0.65
of chemotherapy
2
84/135 90/141
0.60
Prior use of CDK4/6
Yes
inhibitor
No
177/299 190/286
35/66 45/81
0.62
0.70
and/or anthracycline
Prior use of taxane
Taxane alone
Both taxane and anthracycline
Neither taxane nor anthracycline
48/80 47/71
0.62
Anthracycline alone
9/14
141/236 155/247
16/21
0.46
0.70
14/35
17/28
0.34
0.25
0.5
0.75 1
1.5
Size of circle is proportional to the number of events across both treatment groups.
*Three patients from Canada were incorrectly stratified to Rest of World.
Hazard Ratio
Daiichi-Sankyo
31View entire presentation